Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, PR China; Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, PR China; Key Laboratory of Organ Transplantation Zhejiang Province, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, PR China.
Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, PR China; Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, PR China; Key Laboratory of Organ Transplantation Zhejiang Province, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, PR China; Centre for Orthopaedic Research, School of Surgery, University of Western Australia, Western Australia 6009, Australia.
Cancer Lett. 2014 Aug 28;351(1):162-71. doi: 10.1016/j.canlet.2014.05.010. Epub 2014 May 28.
Liver transplantation is a final therapeutic option for treatment of hepatic malignancies, but local recurrence remains high after surgery. However, the underlying mechanisms of local tumor recurrence are still unknown. We speculated that immunological status of transplanted liver may contribute to the progress of tumor development. CT-26 tumor cells are injected into graft after allogeneic or syngeneic liver transplantation. The growth pattern of tumor and the co-relationship of regulatory T cell and effector T cells in liver graft were observed and investigated at 3d, 6d, 9d and 15d post-transplantation. The Hepatic Replacement Area of tumor in allogeneic grafts was significantly larger than that in syngeneic grafts. The activation of tumor growth in allografts was due to the dysfunction of effector T cells mediated by regulatory T cells in liver graft. Using nude mice model, we further confirmed that regulatory T cells from allograft significantly weaken the function of effector T cells in vivo. Our data has showed that MHC-mismatched mice liver transplantation can promote tumor growth in liver graft. For the first time, we demonstrated that susceptibility to tumor development in liver graft is due to the down-regulation of effector T cells' function mediated by the regulatory T cells.
肝移植是治疗肝恶性肿瘤的最终治疗选择,但手术后局部复发率仍然很高。然而,局部肿瘤复发的潜在机制仍不清楚。我们推测移植肝的免疫状态可能有助于肿瘤的发展。将 CT-26 肿瘤细胞注射到同种异体或同基因肝移植后的移植物中。在移植后 3d、6d、9d 和 15d 观察和研究了肿瘤的生长模式以及肝移植物中调节性 T 细胞和效应 T 细胞的共关系。同种异体移植物中的肿瘤肝替代面积明显大于同基因移植物。同种异体移植物中肿瘤生长的激活是由于调节性 T 细胞介导的效应 T 细胞功能障碍。使用裸鼠模型,我们进一步证实,同种异体移植物中的调节性 T 细胞显著削弱了效应 T 细胞在体内的功能。我们的数据表明,MHC 错配小鼠肝移植可促进肝移植物中的肿瘤生长。我们首次证明,肝移植物中对肿瘤发展的易感性是由于调节性 T 细胞介导的效应 T 细胞功能下调所致。